Haemonetics Corporation

NYSE:HAE 株式レポート

時価総額：US$4.3b

Haemonetics 将来の成長

Future 基準チェック /46

Haemonetics利益と収益がそれぞれ年間24.7%と6.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に25% 25.3%なると予測されています。

主要情報

24.7%

収益成長率

25.3%

EPS成長率

Medical Equipment 収益成長17.1%
収益成長率6.2%
将来の株主資本利益率25.0%
アナリストカバレッジ

Good

最終更新日22 Nov 2024

今後の成長に関する最新情報

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

業績と収益の成長予測

NYSE:HAE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/20271,579267N/AN/A6
3/31/20261,456221N/AN/A10
3/31/20251,395177N/AN/A10
9/28/20241,3611243185N/A
6/29/20241,33411569135N/A
3/30/20241,309118115182N/A
12/30/20231,270127129197N/A
9/30/20231,239128199262N/A
7/1/20231,219137176250N/A
4/1/20231,169115163273N/A
12/31/20221,12996128261N/A
10/1/20221,08486116260N/A
7/2/20221,0266888216N/A
4/2/20229934376172N/A
1/1/20229532333106N/A
10/2/20219343154110N/A
7/3/2021903645295N/A
4/3/20218707972109N/A
12/26/2020884108118154N/A
9/26/2020903106120167N/A
6/27/202094696119167N/A
3/28/202098877109158N/A
12/28/20199998081132N/A
9/28/20199886851111N/A
6/29/20199774939139N/A
3/30/20199685540159N/A
12/29/20189524672196N/A
9/29/20189392182204N/A
6/30/201892223N/A205N/A
3/31/201890446N/A220N/A
12/30/2017898-17N/A197N/A
9/30/20178924N/A187N/A
7/1/20178874N/A167N/A
4/1/2017886-26N/A160N/A
12/31/201690016N/A178N/A
10/1/2016906-59N/A155N/A
7/2/2016905-66N/A143N/A
4/2/2016909-56N/A122N/A
12/26/2015893-50N/A124N/A
9/26/201589126N/A119N/A
6/27/201589920N/A123N/A
3/28/201591017N/A127N/A
12/27/201492530N/A123N/A
9/27/201493530N/A142N/A
6/28/201494339N/A140N/A
3/29/201493935N/A140N/A
12/28/201394738N/A116N/A

アナリストによる今後の成長予測

収入対貯蓄率: HAEの予測収益成長率 (年間24.7% ) は 貯蓄率 ( 2.6% ) を上回っています。

収益対市場: HAEの収益 ( 24.7% ) はUS市場 ( 15.4% ) よりも速いペースで成長すると予測されています。

高成長収益: HAEの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: HAEの収益 ( 6.2% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: HAEの収益 ( 6.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HAEの 自己資本利益率 は、3年後には高くなると予測されています ( 25 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y